#ICYMI PepGen’s VP, Clinical Science, Jane Larkindale, participated in #EuroDyma Pharma's Day last month where she provided an update on our FREEDOM-DM1 study. To watch, click https://bit.ly/4bE7YYq #myotonic #DM1
PepGen’s Post
More Relevant Posts
-
Want to know more about Perspectum's proprietary biomarker cT1 and how it's been validated in nearly 100 peer reviewed papers? Perspectum's Pharma Solutions team will be attending #EASL24. Join us to find out why we say: cT1: The Evidence is Here: • To Identify MASH • To Track Treatment Response • To Predict Patient Outcomes • To Support Clinical Trials
To view or add a comment, sign in
-
Oscar Segurado, MD, PhD, Chief Medical Officer at ASC Therapeutics illuminated the stage last night at the 20th BioPharma Clinical Trials Nexus, shedding light on the intricate nuances of Clinical Development. 🌟 With a wealth of expertise, Dr. Segurado navigates us through the lessons learned from Big Pharma, driving success for emerging biotechs💡 #BioPharma #NexusConference #Clinicaldevelopment #Procurementdirect #PharmaBiotech #SanDiego #Clinicaltrials #USconference #BioPharmaNexus
To view or add a comment, sign in
-
Lifescience Dynamics is the Gold Sponsor for this year's Pharma CI USA conference. Will you be attending? If so, come visit our booth or message Peter Kelly, PhD and Alberto Briones, PhD to schedule a meeting in advance. More details to follow! Pharma CI Conference #pharmaciconf #pharmaci #pharmaciconference #competitiveintelligence #biopharma #LifescienceDynamics #PharmaCIUSA2024
I am delighted to confirm that Lifescience Dynamics is the Gold Sponsor for the 2024 Pharma CI USA. Having supported the event for over 17 years, Lifescience Dynamics is so proud to be sponsoring this year’s Pharma CI Conference USA which will take place in Newark, New Jersey on the 25th-26th September. This conference remains the largest and most prestigious event for competitive intelligence in the healthcare industry! Several members of the Lifescience Dynamics’ team will be attending the conference in person, delivering a masterclass, and two thought-provoking co-presentations with industry – more details to follow! Come meet us at our booth, or message Peter Kelly, PhD and Alberto Briones, PhD Briones if you would like to set up a meeting in advance. We look forward to seeing you there! #pharmaciconf #pharmaci #pharmaciconference #competitiveintelligence #biopharma #LifescienceDynamics #PharmaCIUSA2024
To view or add a comment, sign in
-
Planning on attending #DCAT? Join us for our seminar on March 20th led by Dr. Vanessa Zann, Senior Drug Development Consultant. This seminar will explore a series of #drugproduct optimization case studies on solubility enhancement, modified release, and gastric retentive formulations covering in vitro characterization and clinical evaluation, demonstrating how #TranslationalPharmaceutics® was applied to achieve success in each. https://bit.ly/484qMgz
To view or add a comment, sign in
-
🔬🧠 From lead identification to developing a groundbreaking BTK inhibitor, Redx Pharma's success story is a testament to the power of collaboration within our ecosystem. Explore their journey and the impact of precision medicine in our latest whitepaper ➡ http://bit.ly/3XQ26XP
To view or add a comment, sign in
-
MBBS BSc (Gastro&Hep) MRCGP Dip(Resp) Medical Director Perspectum, Health Policy, GPwSI Resp, Former ICP Resp Lead Generalist w interests in pathways; mitigating the asymmetry of knowledge & moral hazards of healthcare
(Own views) A true commitment to Innovation by keeping open eyes, ears and hearts to the advances in technology… to allow the necessary ….EARLY DETECTION of MULTIORGAN, METABOLIC and CANCER disease… the entirety of our current global health burden of multi morbidity , NCDs and aging poor quality health… Looking to how diagnostics and care pathways can augment our patient care and workforce’s capacity to meet our exponential health & social care demands: risk stratification, pre/post operative optimisation, early detection and diagnosis etc etc is possible We’ve known since the 60s… of (Baumols)cost of disease model … PREDICTED today’s unbalanced productivity growth, between different sectors, crushing the health system and national health…. We’ve known healthcare’s technological lag and lack of industrialisation would impede healthcare productivity growth… Our current crisis was predicted ….our innovation however, hasn’t been preemptively implemented …. I can’t go a day without hearing how hard it is to access care or diagnostics or the right clinician … Now more than ever we need commitment to meaningful and equitable implementation … only possible by universal agreement and acknowledgment by our health leaders and organisations…. Please act as ONE for public health ….Not siloed hierarchies … not siloed care… system thinking … overcoming barriers of suspicion and hierarchy in our implementation of innovation… With the general election we need a …. Leap of faith and an arena for those truly dedicated to health innovation…. Conflicts: Perspectum Ltd , Parent of a joyous boy with Duchenne concerned about our future healthcare sustainability at a time we can no longer advocate for him, General practitioner concerned about lack of integrated care and community diagnostics across postcodes and vulnerable groups , concerned citizen Wes Streeting Amanda Pritchard Victoria Atkins NHS England Royal College of Physicians #multiorgan #cancer #raredisease
Want to know more about Perspectum's proprietary biomarker cT1 and how it's been validated in nearly 100 peer reviewed papers? Perspectum's Pharma Solutions team will be attending #EASL24. Join us to find out why we say: cT1: The Evidence is Here: • To Identify MASH • To Track Treatment Response • To Predict Patient Outcomes • To Support Clinical Trials
To view or add a comment, sign in
-
Just a week or so left to book your seat at Vanessa's #DCAT seminar. Translational Pharmaceutics is still the only platform to truly integrate real-time manufacture and clinical testing. Come see how powerful it can be if you're seeking to accelerate your drug development timelines....and we know you are! #translationalpharmaceutics #quotientsciences #drugproductoptimization
Planning on attending #DCAT? Join us for our seminar on March 20th led by Dr. Vanessa Zann, Senior Drug Development Consultant. This seminar will explore a series of #drugproduct optimization case studies on solubility enhancement, modified release, and gastric retentive formulations covering in vitro characterization and clinical evaluation, demonstrating how #TranslationalPharmaceutics® was applied to achieve success in each. https://bit.ly/484qMgz
To view or add a comment, sign in
-
It's nearly here! The Pharma CI Conference is commencing this week and the Lifescience Dynamics team cannot wait to begin. Will you be attending the event? If so reach out to Peter Kelly, PhD or Alberto Briones, PhD to schedule a meeting in advance, or come and visit us at our booth. We look forward to seeing you there. #pharmaciconf #pharmaci #pharmaciconference #competitiveintelligence #biopharma #LifescienceDynamics #PharmaCIUSA2024
I am delighted to confirm that Lifescience Dynamics is the Gold Sponsor for the 2024 Pharma CI USA. Having supported the event for over 17 years, Lifescience Dynamics is so proud to be sponsoring this year’s Pharma CI Conference USA which will take place in Newark, New Jersey on the 25th-26th September. This conference remains the largest and most prestigious event for competitive intelligence in the healthcare industry! Several members of the Lifescience Dynamics’ team will be attending the conference in person, delivering a masterclass, and two thought-provoking co-presentations with industry – more details to follow! Come meet us at our booth, or message Peter Kelly, PhD and Alberto Briones, PhD Briones if you would like to set up a meeting in advance. We look forward to seeing you there! #pharmaciconf #pharmaci #pharmaciconference #competitiveintelligence #biopharma #LifescienceDynamics #PharmaCIUSA2024
To view or add a comment, sign in
-
At Insilico Medicine, patients are the ultimate shareholders. "Our primary responsibility is to the shareholders, but patients are ultimate shareholders, those are the people who are suffering today, and if we can cut one year of drug discovery and delivery time for them, we will do that," said Alex Zhavoronkov, founder and CEO of Insilico Medicine on Pharma.ai Day. #PatientFirst #DrugDiscoveryRevolution #FutureOfHealthcare
To view or add a comment, sign in
-
🔔 Today, we reported our Q2 2024 financial results and provided a corporate update. 🗓️A webcast will start shortly, at 8am ET. Register here: https://bit.ly/3yaalUd. 👨💼 💊 Jason Tardio, experienced multiple sclerosis drug commercialization executive, appointed Chief Operating Officer and President 📢 🔬 Strengthened board of directors with appointment of Simona Skerjanec, senior pharmaceutical executive and thought leader in brain health 🧠 📄 Ongoing, twin phase 3 ENSURE trials in relapsing MS and phase 2 CALLIPER trial in progressive MS remain on track If you can't make it live, you can listen to the recording of our webcast. The link will we available on our website: http://bit.ly/3zvLnfT. Learn more details here: ▶️ https://bit.ly/3AnBALA #Biotechnology #FinancialReporting #FinancialResults #MultipleSclerosis #MS #RMS #ENSURE #PMS #CALLIPER #commercialization #Immunic #IMUX
To view or add a comment, sign in
9,604 followers